High glucose induces transactivation of the human paraoxonase 1 gene in hepatocytes

Metabolism: Clinical and Experimental

Volumn 57, Issue 12, 2008, Pages 1725-1732

  Ikeda, Yukio ^a   Suehiro, Tadashi ^a   Arii, Kaoru ^a   Kumon, Yoshitaka ^a   Hashimoto, Kozo ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BISINDOLYLMALEIMIDE; DIACYLGLYCEROL; GLUCOSE; LUCIFERASE; MESSENGER RNA; MITHRAMYCIN; PROTEIN KINASE C; TRANSCRIPTION FACTOR SP1;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIVER CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; TIME; TRANSACTIVATION;

ARYLDIALKYLPHOSPHATASE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSE; HEPATOCYTES; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 55649089410     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.07.032     Document Type: Article

References (44)

1. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., et al. The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff memorial lecture. Arterioscler Thromb Vasc Biol 16 (1996) 831-842
2. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
3. Berliner J.A., and Heinecke J.W. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20 (1996) 707-727
4. Galle J., Hansen-Hagge T., Wanner C., and Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 185 (2006) 219-226
5. Mertens A., and Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 15 (2001) 2073-2084
6. Barter P.J., and Rye K.A. Molecular mechanisms of reverse cholesterol transport. Curr Opin Lipidol 7 (1996) 82-87
7. Brewer Jr. H.B. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 387-391
8. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., and Fonarow G.C. High-density lipoprotein function. Recent advances. J Am Coll Cardiol 46 (2005) 1792-1798
9. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., and Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 41 (2006) 1031-1040
10. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006) 1352-1364
11. Blatter M.C., James R.W., Messmer S., Barja F., and Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem 211 (1993) 871-879
12. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991) 152-154
13. Mackness M.I., Arrol S., Abbott C., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
14. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
15. Shih D.M., Xia Y.R., Wang X.P., Miller E., Castellani L.W., Subbanagounder G., et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275 (2000) 17527-17535
16. Tward A., Xia Y.R., Wang X.P., Shi Y.S., Park C., Castellani L.W., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
17. Rozenberg O., Shih D.M., and Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 181 (2005) 9-18
18. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
19. Scott J.A., and King G.L. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci 1031 (2004) 204-213
20. Fridlyand L.E., and Philipson L.H. Oxidative reactive species in cell injury. Mechanisms in diabetes mellitus and therapeutic approaches. Ann N Y Acad Sci 1066 (2005) 136-151
21. Mastorikou M., Mackness M., and Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes 55 (2006) 3099-3103
22. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-199
23. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscl Thromb Vasc Biol 15 (1995) 1812-1818
24. Boemi M., Leviev I., Sirolla C., Pieri C., Marra M., and James R.W. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis 155 (2001) 229-235
25. Ikeda Y., Suehiro T., Inoue M., Nakauchi Y., Morita T., Arii K., et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47 (1998) 598-602
26. Mackness B., Mackness M.I., Arrol S., Turkie W., Julier K., Abuasha B., et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 139 (1998) 341-349
27. Inoue M., Suehiro T., Nakamura T., Ikeda Y., Kumon Y., and Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 49 (2000) 1400-1405
28. Patel B.N., Mackness M.I., Harty D.W., Arrol S., Boot-Handford R.P., and Durrington P.N. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochim Biophys Acta 1035 (1990) 113-116
29. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., et al. Glycation impairs high-density lipoprotein function. Diabetologia 43 (2000) 312-320
30. Ferretti G., Bacchetti T., Marchionni C., Caldarelli L., and Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38 (2001) 163-169
31. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
32. Karabina S.A.P., Lehner A.N., Frank E., Parthasarathy S., and Santanam N. Oxidative inactivation of paraoxonase. Implications in diabetes mellitus and atherosclerosis. Biochim Biophys Acta 1725 (2005) 213-221
33. Witztum J.L., Fisher M., Pietro T., Steinbrecher U.P., and Elam R.L. Nonenzymatic glucosylation of high-density lipoprotein accelerates its catabolism in guinea pigs. Diabetes 31 (1982) 1029-1032
34. Osaki F., Ikeda Y., Suehiro T., Ota K., Tsuzura S., Arii K., et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis 176 (2004) 279-287
35. Laybutt D.R., Schmitz-Peiffer C., Saha A.K., Ruderman N.B., Biden T.J., and Kraegen E.W. Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 277 (1999) E1070-E1076
36. Nakajima K., Yamauchi K., Shigematsu S., Ikeo S., Komatsu M., Aizawa T., et al. Selective attenuation of metabolic branch of insulin receptor down-signaling by high glucose in a hepatoma cell line, HepG2 cells. J Biol Chem 275 (2000) 20880-20886
37. Kawamura M., Heinecke J.W., and Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94 (1994) 771-778
38. Mowri H.O., Frei B., and Keaney Jr. J.F. Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radic Biol Med 29 (2000) 814-824
39. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91 (1995) 2488-2496
40. Bowie A., Owens D., Collins P., Johnson A., and Tomkin G.H. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?. Atherosclerosis 102 (1993) 63-67
41. Sayeski P.P., and Kudlow J.E. Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-α gene transcription. J Biol Chem 271 (1996) 15237-15243
42. Chen Y.Q., Su M., Walia R.R., Hao Q., Covington J.W., and Vaughan D.E. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem 273 (1998) 8225-8231
43. Chae Y.M., Park K.K., Magae J., Lee I.S., Kim C.H., Kim H.C., et al. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys Res Commun 319 (2004) 550-555
44. Kumon Y., Suehiro T., Ikeda Y., and Hashimoto K. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1β and tumor necrosis factor-α, but is upregulated by interleukin-6. Life Sci 73 (2003) 2807-2815